Evidence Level
Glutathione (Liver Support) is essential for maintaining liver health and detoxification processes. Hayes et al. (2005) highlighted the role of glutathione S-transferases in neutralizing toxic substances within the liver, emphasizing their importance in hepatic function. Prescott et al. (1979) established intravenous N-acetylcysteine (NAC) as a standard treatment for acetaminophen toxicity by restoring hepatic glutathione levels, underscoring its therapeutic value. Recent clinical evidence from Honda et al. (2017) demonstrated the efficacy of direct glutathione supplementation in managing nonalcoholic fatty liver disease (NAFLD), offering a novel approach to liver support.
Lu (2013) linked glutathione depletion to various liver diseases, emphasizing its protective role. However, oral glutathione supplementation faces challenges related to bioavailability, prompting innovations such as liposomal technology and S-acetyl forms. NAC remains a cost-effective strategy for elevating hepatic GSH levels.
Recent studies have explored the broader implications of glutathione metabolism. Mohideen et al. (2023) found increased glutathione peroxidase activity in oral cancer tissues, while noting decreased activity in erythrocytes, highlighting its complex role in oxidative stress and disease states. Zhang et al. (2019) identified genetic variations in GSTM1 and GSTT1 associated with an increased risk of anti-tuberculosis drug-induced liver injury, particularly among East Asians and Indians, underscoring the need for individualized approaches to supplementation.
Overall, glutathione's role in liver health is well-established, with ongoing research exploring its therapeutic potential and genetic influences on disease susceptibility.